首页   按字顺浏览 期刊浏览 卷期浏览 The Effect of Recombinant Human Insulin-Like Growth Factor-I on Chronic Puromycin Amino...
The Effect of Recombinant Human Insulin-Like Growth Factor-I on Chronic Puromycin Aminonucleoside Nephropathy in Rats

 

作者: TRACHTMAN HOWARD,   MAESAKA JOHN,   FUTTERWEIT STEPHEN,   MA CHAN,   VALDERRAMA ELSA,   CHAN JAMES,   CHAN WINNIE,  

 

期刊: Pediatric Research  (OVID Available online 1996)
卷期: Volume 39, issue 1  

页码: 13-19

 

ISSN:0031-3998

 

年代: 1996

 

出版商: OVID

 

数据来源: OVID

 

摘要:

We recently demonstrated that recombinant hGH exacerbates renal functional and structural injury in chronic puromycin aminonucleoside (PAN) nephropathy, an experimental model of glomerular disease. Therefore, we examined whether recombinant human (rh) IGF-I is a safer alternative for the treatment of growth failure in rats with chronic PAN nephropathy. The glomerulopathy was induced by seven serial injections of PAN over 12 wk. Experimental animals(n= 6) received rhIGF-I, 400 μg/d, whereas control rats(n= 6) received the vehicle. rhIGF-I improved weight gain by 14%(p< 0.05), without altering hematocrit or blood pressure in rats with renal disease. Urinary protein excretion was unaltered by rhIGF-I treatment in rats with chronic PAN nephropathy. After 12 wk, the inulin clearance was higher in rhIGF-I-treated rats, 0.48 ± 0.08versus0.24 ± 0.06 mL/min/100 g of body weight in untreated PAN nephropathy animals,p< 0.05. The improvement in GFR was not associated with enhanced glomerular hypertrophy or increased segmental glomerulosclerosis, tubulointerstitial injury, or renal cortical malondialdehyde content. In rats with PAN nephropathy, administration of rhIGF-I increased IGF-I and GH receptor gene expression, without altering the steady state level of IGF-I receptor mRNA. In normal rats with intact kidneys, rhIGF-I administration (n= 4) did not alter weight gain, blood pressure, proteinuria, GFR, glomerular planar area, renal cortical malondialdehyde content, or glomerular or tubulointerstitial damage, compared with untreated animals (n= 4). rhIGF-I treatment reduced the steady state renal IGF-I mRNA level but did not modify gene expression of the IGF-I or GH receptors. We conclude that:1) administration of rhIGF-I improves growth and GFR in rats with chronic PAN nephropathy and2) unlike rhGH, long-term use of rhIGF-I does not worsen renal functional and structural injury in this disease model.Abbreviations: BW,body weight;CRF,chronic renal failure;FSGS,focal segmental glomerulosclerosis;PAN,puromycin aminonucleoside;rh,recombinant human

 



返 回